Does the media favor VTGN or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 2 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 1 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.00 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that VistaGen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GDTC or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, GDTC or VBIO?

CytoMed Therapeutics has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CytoMed Therapeutics $250K 42.26 -$3.10M N/A N/A Valion Bio, Inc. Common Stock $780K 3.19 -$8.88M -$6.37 N/A

Is GDTC or VBIO more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets CytoMed Therapeutics N/A N/A N/A Valion Bio, Inc. Common Stock N/A -193.17% -67.10%

Do analysts recommend INAB or VBIO?

IN8bio currently has a consensus price target of $4.00, suggesting a potential upside of 244.83%. Given IN8bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe IN8bio is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INAB or VBIO more profitable?

IN8bio's return on equity of -91.18% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Valion Bio, Inc. Common Stock N/A -193.17% -67.10%

Do analysts recommend SNTI or VBIO?

Senti Biosciences currently has a consensus price target of $10.00, suggesting a potential upside of 2,831.69%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Senti Biosciences is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SNTI or VBIO more profitable?

Valion Bio, Inc. Common Stock's return on equity of -193.17% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -1,629.80% -119.72% Valion Bio, Inc. Common Stock N/A -193.17% -67.10%

Do analysts rate APRE or VBIO?

Aprea Therapeutics presently has a consensus price target of $3.07, suggesting a potential upside of 280.34%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to APRE or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.06 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aprea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Valion Bio, Inc. Common Stock (VBIO) Competitors

$2.80 -0.32 (-10.26%)

As of 09/3/2026 04:00 PM Eastern

Compare

VBIO vs. VTGN, GDTC, INAB, SNTI, and APRE

Should you buy Valion Bio, Inc. Common Stock stock or one of its competitors? Valion Bio, Inc. Common Stock's main competitors and comparable companies include VistaGen Therapeutics (VTGN), CytoMed Therapeutics (GDTC), IN8bio (INAB), Senti Biosciences (SNTI), and Aprea Therapeutics (APRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Valion Bio, Inc. Common Stock compare to VistaGen Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

VistaGen Therapeutics presently has a consensus target price of $0.95, indicating a potential upside of 285.87%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe VistaGen Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VistaGen Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. VistaGen Therapeutics' return on equity of -152.59% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than VistaGen Therapeutics. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	8.60	-$69.68M	-$1.66	N/A
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A

In the previous week, Valion Bio, Inc. Common Stock had 2 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 1 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.00 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that VistaGen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

VistaGen Therapeutics beats Valion Bio, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to CytoMed Therapeutics?

CytoMed Therapeutics (NASDAQ:GDTC) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

CytoMed Therapeutics' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

CytoMed Therapeutics has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250K	42.26	-$3.10M	N/A	N/A
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 0 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.00 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that CytoMed Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CytoMed Therapeutics	Neutral
Valion Bio, Inc. Common Stock	Neutral

Summary

CytoMed Therapeutics and Valion Bio, Inc. Common Stock tied by winning 5 of the 10 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to IN8bio?

IN8bio (NASDAQ:INAB) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

IN8bio's return on equity of -91.18% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

IN8bio has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 14.5% of IN8bio shares are owned by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valion Bio, Inc. Common Stock has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A

IN8bio currently has a consensus price target of $4.00, suggesting a potential upside of 244.83%. Given IN8bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe IN8bio is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than IN8bio. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 0 mentions for IN8bio. IN8bio's average media sentiment score of 0.00 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that IN8bio is being referred to more favorably in the media.

Company	Overall Sentiment
IN8bio	Neutral
Valion Bio, Inc. Common Stock	Neutral

Summary

IN8bio beats Valion Bio, Inc. Common Stock on 8 of the 14 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Senti Biosciences currently has a consensus price target of $10.00, suggesting a potential upside of 2,831.69%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Senti Biosciences is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Senti Biosciences has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 0 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.00 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Neutral
Valion Bio, Inc. Common Stock	Neutral

Valion Bio, Inc. Common Stock has higher revenue and earnings than Senti Biosciences. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	531.26	-$61.44M	-$1.77	N/A
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A

Valion Bio, Inc. Common Stock's return on equity of -193.17% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-1,629.80%	-119.72%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

Summary

Senti Biosciences beats Valion Bio, Inc. Common Stock on 11 of the 16 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Aprea Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Valion Bio, Inc. Common Stock has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	35.00	-$12.60M	-$1.08	N/A
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

Aprea Therapeutics presently has a consensus price target of $3.07, suggesting a potential upside of 280.34%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.06 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aprea Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

Summary

Aprea Therapeutics beats Valion Bio, Inc. Common Stock on 10 of the 16 factors compared between the two stocks.

Get Valion Bio, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VBIO vs. The Competition

Export

Metric	Valion Bio, Inc. Common Stock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.77M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.44	12.66	273.28	25.38
Price / Sales	3.19	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.59	16.29	12.89	6.14
Net Income	-$8.88M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-7.36%	0.34%	0.61%	-0.27%
1 Month Performance	-66.30%	8.52%	5.73%	0.68%
1 Year Performance	-96.15%	52.66%	25.37%	14.84%

Valion Bio, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VBIO Valion Bio, Inc. Common Stock	0.2954 of 5 stars	$2.80 -10.3%	N/A	-96.3%	$2.77M	$780K	N/A	10	Gap Down
VTGN VistaGen Therapeutics	1.9259 of 5 stars	$0.25 +1.1%	$0.95 +286.2%	-93.3%	$10.80M	$1.27M	N/A	40	Analyst Forecast Gap Up
GDTC CytoMed Therapeutics	0.4208 of 5 stars	$0.90 -1.4%	N/A	-54.3%	$10.75M	$250K	N/A	N/A	Gap Down
INAB IN8bio	2.3811 of 5 stars	$1.10 +0.9%	$4.00 +263.6%	-47.5%	$10.75M	N/A	N/A	20
SNTI Senti Biosciences	2.9043 of 5 stars	$0.34 +0.6%	$10.00 +2,824.8%	-76.4%	$10.59M	$20K	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VBIO) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. VTGN, GDTC, INAB, SNTI, and APRE

How does Valion Bio, Inc. Common Stock compare to VistaGen Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to CytoMed Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to IN8bio?

Summary

How does Valion Bio, Inc. Common Stock compare to Senti Biosciences?

Summary

How does Valion Bio, Inc. Common Stock compare to Aprea Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. VTGN, GDTC, INAB, SNTI, and APRE

How does Valion Bio, Inc. Common Stock compare to VistaGen Therapeutics?

Do analysts recommend VTGN or VBIO?

Which has more risk and volatility, VTGN or VBIO?

Is VTGN or VBIO more profitable?

Do institutionals & insiders believe in VTGN or VBIO?

Which has preferable earnings and valuation, VTGN or VBIO?

Does the media favor VTGN or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to CytoMed Therapeutics?

Is GDTC or VBIO more profitable?

Do insiders and institutionals have more ownership in GDTC or VBIO?

Do analysts rate GDTC or VBIO?

Which has more risk and volatility, GDTC or VBIO?

Which has preferable valuation and earnings, GDTC or VBIO?

Does the media favor GDTC or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to IN8bio?

Is INAB or VBIO more profitable?

Which has more volatility & risk, INAB or VBIO?

Do institutionals and insiders have more ownership in INAB or VBIO?

Which has better valuation & earnings, INAB or VBIO?

Do analysts recommend INAB or VBIO?

Does the media refer more to INAB or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to Senti Biosciences?

Do insiders & institutionals hold more shares of SNTI or VBIO?

Do analysts recommend SNTI or VBIO?

Which has more volatility and risk, SNTI or VBIO?

Does the media prefer SNTI or VBIO?

Which has better earnings & valuation, SNTI or VBIO?

Is SNTI or VBIO more profitable?

Summary

How does Valion Bio, Inc. Common Stock compare to Aprea Therapeutics?

Which has stronger valuation & earnings, APRE or VBIO?

Is APRE or VBIO more profitable?

Do analysts rate APRE or VBIO?

Do institutionals & insiders hold more shares of APRE or VBIO?

Does the media refer more to APRE or VBIO?

Which has more risk & volatility, APRE or VBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools